Cargando…

Predicting serum ferritin levels in patients with iron overload treated with the film‐coated tablet of deferasirox during the ECLIPSE study

Detalles Bibliográficos
Autores principales:	Taher, Ali T., Weber, Sebastian, Han, Jackie, Bruederle, Andreas, Porter, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	E‐only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587503/ https://www.ncbi.nlm.nih.gov/pubmed/30346059 http://dx.doi.org/10.1002/ajh.25322

Ejemplares similares

Influence of patient‐reported outcomes on the treatment effect of deferasirox film‐coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis
por: Taher, Ali T., et al.
Publicado: (2019)

New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study
por: Taher, Ali T., et al.
Publicado: (2017)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
por: Porter, John B, et al.
Publicado: (2011)

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study
por: Tartaglione, Immacolata, et al.
Publicado: (2020)

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
por: Taher, Ali T., et al.
Publicado: (2018)

Iron overload in patients with rare hereditary hemolytic anemia: Evidence‐based suggestion on whom and how to screen
por: van Straaten, Stephanie, et al.
Publicado: (2018)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
por: Pathare, Anil, et al.
Publicado: (2009)

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions
por: Chalmers, Anna W, et al.
Publicado: (2016)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

DETERMINATION OF FERRITIN AND HEMOSIDERIN IRON IN PATIENTS WITH NORMAL IRON STORES AND IRON OVERLOAD BY SERUM FERRITIN KINETICS
por: SAITO, HIROSHI, et al.
Publicado: (2012)

Renal Function in Patients with Thalassemia Major Receiving Exjade(®) Dispersible Tablets and a New Film-coated Tablet Formulation of Deferasirox (Nanojade(®))
por: Falahati, Vahid, et al.
Publicado: (2022)

Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia
por: Viprakasit, Vip, et al.
Publicado: (2023)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
por: Adramerina, Alkistis, et al.
Publicado: (2022)

Juvenile hemochromatosis: HAMP mutation and severe iron overload treated with phlebotomies and deferasirox
por: Lescano, Manuel A, et al.
Publicado: (2017)

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
por: Daar, Shahina, et al.
Publicado: (2009)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
por: Almadhani, Shaimaa, et al.
Publicado: (2023)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

PB2565: TRANSFUSIONAL IRON OVERLOAD AND ASSOCIATED COMPLICATIONS IN HEMATOLOGY DISORDERS PATIENTS
por: Romanenko, Nikolay, et al.
Publicado: (2023)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran
por: Saiyarsarai, Parisa, et al.
Publicado: (2020)

Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory
por: Donker, Albertine E., et al.
Publicado: (2016)

Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2018)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow
por: Shen, J.C., et al.
Publicado: (2017)

Transformation rate between ferritin and hemosiderin assayed by serum ferritin kinetics in patients with normal iron stores and iron overload
por: Saito, Hiroshi, et al.
Publicado: (2015)

Determination of Serum Ferritin Glycosylation in Hyperferritinemia Associated to Iron Overload and Inflammation.
por: Gasser, Bethina Isasi
Publicado: (2009)

Iron Chelation Therapy with Deferasirox Results in Improvement of Liver Enzyme Level in Patients with Iron Overload-Associated Liver Dysfunction
por: Miura, Yasuo, et al.
Publicado: (2010)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

PB2564: COVID-19 AND FERRITIN
por: Kuiavovych, Bohdana, et al.
Publicado: (2023)

PB1929: PRELIMINARY STUDY OF EVALUATION IRON OVERLOAD MYOCARDIAL INJURY BY LOAD CT MYOCARDIAL PERFUSION IMAGING
por: Zhang, Y., et al.
Publicado: (2022)

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2011)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2017)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_95ijkiplsue0mjcuv6khdtin44